Top Markets
#1 Pleasing Gold Pleasing Gold +1,501.46%
#2 Ontology Gas Ontology Gas +131.75%
#3 PulseChain PulseChain +61.85%
#4 Osmosis Osmosis +35.55%
#5 BOOK OF MEME BOOK OF MEME +31.03%
#6 Ontology Ontology +30.60%
#7 Neiro Neiro +30.07%
#8 Collect on Fanable Collect on Fanable +28.80%
#9 Unit Pump Unit Pump +28.63%
#10 Pump.fun Pump.fun +28.63%
Coin of the day
Pleasing Gold Pleasing Gold
Settings
Language
ENGLISH
Currency
USD
Theme
Mendus AB (publ) Mendus AB (publ)

Mendus AB (publ)

IMMU
Rank in Stocks #25836
Mendus AB (publ), a biopharmaceutical entity formerly known as Immunicum AB... Mendus AB (publ), a biopharmaceutical entity formerly known as Immunicum AB (publ) until its name change in June 2022, specializes in developing immunotherapies and vaccines designed to prevent cancer recurrence. Its primary investigational compound, ilixadencel, is currently progressing through a Phase II MERECA clinical study for kidney cancer, alongside Phase I/II trials targeting liver cancer and gastrointestinal stromal tumors. Additionally, the company is advancing DCP-001, which is undergoing Phase II ADVANCE-II clinical research for acute myeloid leukemia and Phase I/II ALISON trials for ovarian cancers. Mendus maintains research partnerships with PCI Biotech Holding ASA to explore novel cancer vaccination approaches and with the Icahn School of Medicine at Mount Sinai. Founded in 2002, Mendus AB is headquartered in Stockholm, Sweden.
Share Price
$0.74834668
Market Cap
$45.86M
Change (1 day)
-0.15%
Change (1 year)
-6.28%
Country
SE
Trade Mendus AB (publ) (IMMU)

Category

Healthcare
Earnings for Mendus AB (publ) (IMMU)
Earnings in 2026 TTM: 0
According to Mendus AB (publ) latest financial reports the company's current earnings are 0. In 2026 the company made an earning of 0, equal to its 2026 earnings that were of 0. The earnings displayed on this page are the earnings before interest and taxes or simply EBIT.
Earnings history for Mendus AB (publ) from 2026 to 2026
Earnings at the end of each year
Year Earnings Change
Not enough data for the provided dates.
Earnings for similar companies or competitors
Company Earnings Earnings Difference Country
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
$5.27B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
$1.95B -
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
$1.61B -
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
- -
CH
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
$-3.09B -
US